The market for biosimilar versions of AbbVie’s (NYSE: ABBV) mega-blockbuster TNF blocker Humira (adalimumab) is hotting up, with a major price reduction from Boehringer Ingelheim.
The company already sells a branded version at a 5% discount, known as Cyltezo (adalimumab-adbm), following its launch just a few months ago.
The German drugmaker has now revealed plans to slash the price of the product, selling it without branding at a wholesale acquisition cost (WAC) around four-fifths lower than the original.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze